头孢吡肟与头孢他啶作为血液系统恶性肿瘤中性粒细胞减少患者发热的经验性治疗药物比较
Cefepime versus ceftazidime as empirical therapy for fever in neutropenic patients with haematological malignancies.
作者信息
Ghalaut P S, Chaudhry Uma, Ghalaut Veena Singh, Aggarwal Sameer, Sood Vinny, Dixit Gaurav
机构信息
Departments of Medicine, Microbiology and Biochemistry Pt., B.D.Sharma Post Graduate Institute of Medical Sciences, 216J, Medical Campus, Rohtak, 124 001 India.
出版信息
Indian J Hematol Blood Transfus. 2007 Dec;23(3-4):104-6. doi: 10.1007/s12288-008-0007-x. Epub 2008 Mar 19.
An open randomized comparative study was conducted to evaluate the efficacy of Cefepime (2 gm iv. 8 hr.) vs. ceftazidime (2 gm iv. every 8 hr.) in empirical therapy of febrile neutropenic patients. A total of 40 eligible febrile episodes were randomized to be treated with study regimen. Twenty febrile episodes were treated with cefepime and 20 were treated with ceftazidime. The two groups were comparable in terms of age, sex, height, underlying neoplasm, number of pretherapy neutrophils, duration of neutropenia. The overall therapeutic success rate of cetepime group (60%) was comparable to that of ceftazidime group (55%). The results of this study suggest that cefepime is an effective and safe agent in empirical therapy of febrile episode in neutropenic patient and its efficacy is comparable with that of ceftazidime.
进行了一项开放性随机对照研究，以评估头孢吡肟（静脉注射2克，每8小时一次）与头孢他啶（静脉注射2克，每8小时一次）在发热性中性粒细胞减少患者经验性治疗中的疗效。共有40例符合条件的发热发作被随机分配接受研究方案治疗。20例发热发作接受头孢吡肟治疗，20例接受头孢他啶治疗。两组在年龄、性别、身高、潜在肿瘤、治疗前中性粒细胞数量、中性粒细胞减少持续时间方面具有可比性。头孢吡肟组的总体治疗成功率（60%）与头孢他啶组（55%）相当。本研究结果表明，头孢吡肟在中性粒细胞减少患者发热发作的经验性治疗中是一种有效且安全的药物，其疗效与头孢他啶相当。
Zotero 插件